Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
SOPHiA GENETICS
SOPH
SOPHiA GENETICS
Revenue Lags And Margin Pressure Will Improve Eventually
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
42.2% undervalued
intrinsic discount
16 Aug
US$3.47
Loading
1Y
6.4%
7D
9.1%
Author's Valuation
US$6.0
42.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
42.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-93m
111m
2019
2021
2023
2025
2027
2028
Revenue US$111.5m
Earnings US$9.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
20.09%
Healthtech revenue growth rate
4.96%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.05%
Calculation
US$9.77m
Earnings '28
x
55.07x
PE Ratio '28
=
US$538.02m
Market Cap '28
US$538.02m
Market Cap '28
/
71.87m
No. shares '28
=
US$7.49
Share Price '28
US$7.49
Share Price '28
Discounted to 2025 @ 8.09% p.a.
=
US$5.93
Fair Value '25
